Sign In
Buy INCY
$119.80
-0.800 (-0.663%)
At Close: Aug 05, 2026
MorphoSys FDA Approval, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:MOR)
04:12pm, Monday, 03'rd Aug 2020
MorphoSys receives FDA approval for Monjuvi. Brigham president tenders resignation from Moderna board after conflict of interest.
Dow Jones Today, Stocks Rise As Microsoft Courts TikTok; Varian Soars On Siemens Deal; Incyte, Co-Diagnostics FDA News
01:55pm, Monday, 03'rd Aug 2020
Incyte paced the Nasdaq, Microsoft led the Dow Jones, and stock futures rose as global markets rallied on strong manufacturing data.
FDA approves MorphoSys, Incyte’s drug for vulnerable lymphoma population
01:19pm, Monday, 03'rd Aug 2020
The FDA approved Monjuvi for second-line diffuse large B-cell lymphoma. Though the drug has the same antigen target as approved CAR-T cell therapies, it is designed for patients unable to tolerate suc
Is a Surprise Coming for Incyte (INCY) This Earnings Season?
12:38pm, Monday, 03'rd Aug 2020
Incyte (INCY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Incyte/Morphosys take on CAR-Ts as lymphoma antibody Monjuvi approved in US -
10:49am, Monday, 03'rd Aug 2020
Incyte and Morphosys’ Monjuvi antibody therapy has been approved for certain patients with lymphoma, as the companies hope to provide a more convenient alternative to expensive and cumbersome CAR-T
Incyte, MorphoSys Win FDA Nod For ‘Key Revenue Driver’ Tafasitamab
10:08am, Monday, 03'rd Aug 2020
Incyte (INCY) and MorphoSys (MOR) have announced that the US Food and Drug Administration (FDA) has approved Monjuvi (tafasitamab-cxix) plus lenalidomide
Is a Surprise Coming for Incyte (INCY) This Earnings Season?
08:38am, Monday, 03'rd Aug 2020
Incyte (INCY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Incyte, MorphoSys Win FDA Nod For ‘Key Revenue Driver’ Tafasitamab
06:08am, Monday, 03'rd Aug 2020
Incyte (INCY) and MorphoSys (MOR) have announced that the US Food and Drug Administration (FDA) has approved Monjuvi (tafasitamab-cxix) plus lenalidomide for adults with relapsed or refractory diffu
Disney, T-Mobile, CVS, Activision Blizzard, and Other Stocks for Investors to Watch This Week
07:00pm, Sunday, 02'nd Aug 2020
Second-quarter earnings season continues with results from Disney, T-Mobile, Fox, ViacomCBS, and Clorox. Video-game makers Take-Two and Activision Blizzard also report. Plus, July jobs data.
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
12:00am, Sunday, 02'nd Aug 2020
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
Zurcher Kantonalbank Zurich Cantonalbank Increases Stock Holdings in Incyte Co. (NASDAQ:INCY)
10:34am, Saturday, 01'st Aug 2020
Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Incyte Co. (NASDAQ:INCY) by 10.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securi
Allegiant Flies Above the Pack With Its Budget-Meets-Leisure Formula
12:37am, Saturday, 01'st Aug 2020
In a year in which airlines have gotten hammered by the pandemic, a carrier with ultralow costs and flexible scheduling takes the lead. Not that the flight may not get a little rough.
Xencor Earns Milestone Payment from MorphoSys for FDA Approval of Monjuvi® (tafasitamab-cxix) in the United States
12:00am, Saturday, 01'st Aug 2020
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and au
FDA Approves Monjuvi® (tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory DLBCL
The jobs report and congressional politics may matter more for markets than earnings in the week ahead
09:06pm, Friday, 31'st Jul 2020
The market could lose some exuberance as the calendar turns to August, and investors await Friday's July employment report.
